Skip to main content

BioIVT Buys Durham's Qualyst Transporter Solutions

BioreclamationIVT, a New York company that sells biospecimens and related services, primarily for drug safety testing, has purchased Durham’s Qualyst Transporter Solutions for an undisclosed sum.
 

Getting Down to the Roots of Breeding Better Corn

Duke University scientist Philip Benfey, Ph.D., has co-founded his second startup company, Durham-based Hi Fidelity Genetics, to use data on roots to breed and sell corn seed with desirable traits.

Innovate Gets Orphan Status for Pediatric Ulcerative Colitis Drug

Raleigh-based Innovate Biopharmaceuticals has received U.S. Food and Drug Administration orphan drug designation for an experimental oral drug to treat pediatric ulcerative colitis.

GSK’s Jack Bailey: NCBiotech Roots Launch High-Profile Career in Big Pharma

Jack Bailey, president of U.S. Pharmaceuticals for GlaxoSmithKline, says an internship he served at the Biotech Center was a major influence in his successful career as a global pharmaceutical company leader.

FDA Approves Bioventus’ Therapy for Knee Pain

Durham-based Bioventus, a global orthobiologics company, has received approval from the U.S. Food and Drug Administration to market Durolane, a single-injection joint lubricant for treating pain from knee osteoarthritis.

16 Bioscience Companies Awarded $1 Million in State Grants

Sixteen life science companies throughout North Carolina have received just over $1 million in grants from a state program to support their development of new technologies and products.

$100 Early Discount Ends Friday for SEBIO Forum in Pinehurst

Investors and other life science professionals have just a few more days to register at a discounted price for the 2017 SEBIO Investor and Partnering Forum in Pinehurst this fall.

NCBiotech Funding Helps Western NC Life Scientists

A $76,527 Institutional Development Grant from the North Carolina Biotechnology Center earlier in 2017 has given Western North Carolina university scientists and students access to an important new research tool.

Grid Therapeutics Acquires Rights to Antibody for Cancer Immunotherapy

Durham-based Grid Therapeutics, an oncology-focused biotechnology company, has signed an exclusive license agreement with Duke University to develop the first human-derived antibody as a targeted immunotherapy for cancer. 

NCBiotech Portfolio Companies Raise $128 Million in Q4

Eighteen bioscience companies previously funded by NCBiotech loans raised more than $128 million in follow-on funding from other sources during the fourth quarter of 2016-17.

Pages

Subscribe to RSS - Life Sciences